The small inhibitor WM-1119 effectively targets KAT6A-rearranged AML, but not KMT2A-rearranged AML, despite shared KAT6 genetic dependency.
Journal
Journal of hematology & oncology
ISSN: 1756-8722
Titre abrégé: J Hematol Oncol
Pays: England
ID NLM: 101468937
Informations de publication
Date de publication:
08 Oct 2024
08 Oct 2024
Historique:
received:
10
05
2024
accepted:
20
09
2024
medline:
9
10
2024
pubmed:
9
10
2024
entrez:
8
10
2024
Statut:
epublish
Résumé
The epigenetic factors KAT6A (MOZ/MYST3) and KMT2A (MLL/MLL1) interact in normal hematopoiesis to regulate progenitors' self-renewal. Both proteins are recurrently translocated in AML, leading to impairment of critical differentiation pathways in these malignant cells. We evaluated the potential of different KAT6A therapeutic targeting strategies to alter the growth of KAT6A and KMT2A rearranged AMLs. We investigated the action and potential mechanisms of the first-in-class KAT6A inhibitor, WM-1119 in KAT6A and KMT2A rearranged (KAT6Ar and KMT2Ar) AML using cellular (flow cytometry, colony assays, cell growth) and molecular (shRNA knock-down, CRISPR knock-out, bulk and single-cell RNA-seq, ChIP-seq) assays. We also used two novel genetic murine KAT6A models combined with the most common KMT2Ar AML, KMT2A::MLLT3 AML. In these murine models, the catalytic activity of KAT6A, or the whole protein, can be conditionally abrogated or deleted. These models allowed us to compare the effects of specific KAT6A KAT activity inhibition with the complete deletion of the whole protein. Finally, we also tested these therapeutic approaches on human AML cell lines and primary patient AMLs. We found that WM-1119 completely abrogated the proliferative and clonogenic potential of KAT6Ar cells in vitro. WM-1119 treatment was associated with a dramatic increase in myeloid differentiation program. The treatment also decreased stemness and leukemia pathways at the transcriptome level and led to loss of binding of the fusion protein at critical regulators of these pathways. In contrast, our pharmacologic and genetic results indicate that the catalytic activity of KAT6A plays a more limited role in KMT2Ar leukemogenicity, while targeting the whole KAT6A protein dramatically affects leukemic potential in murine KMT2A::MLLT3 AML. Our study indicates that inhibiting KAT6A KAT activity holds compelling promise for KAT6Ar AML patients. In contrast, targeted degradation of KAT6A, and not just its catalytic activity, may represent a more appropriate therapeutic approach for KMT2Ar AMLs.
Sections du résumé
BACKGROUND
BACKGROUND
The epigenetic factors KAT6A (MOZ/MYST3) and KMT2A (MLL/MLL1) interact in normal hematopoiesis to regulate progenitors' self-renewal. Both proteins are recurrently translocated in AML, leading to impairment of critical differentiation pathways in these malignant cells. We evaluated the potential of different KAT6A therapeutic targeting strategies to alter the growth of KAT6A and KMT2A rearranged AMLs.
METHODS
METHODS
We investigated the action and potential mechanisms of the first-in-class KAT6A inhibitor, WM-1119 in KAT6A and KMT2A rearranged (KAT6Ar and KMT2Ar) AML using cellular (flow cytometry, colony assays, cell growth) and molecular (shRNA knock-down, CRISPR knock-out, bulk and single-cell RNA-seq, ChIP-seq) assays. We also used two novel genetic murine KAT6A models combined with the most common KMT2Ar AML, KMT2A::MLLT3 AML. In these murine models, the catalytic activity of KAT6A, or the whole protein, can be conditionally abrogated or deleted. These models allowed us to compare the effects of specific KAT6A KAT activity inhibition with the complete deletion of the whole protein. Finally, we also tested these therapeutic approaches on human AML cell lines and primary patient AMLs.
RESULTS
RESULTS
We found that WM-1119 completely abrogated the proliferative and clonogenic potential of KAT6Ar cells in vitro. WM-1119 treatment was associated with a dramatic increase in myeloid differentiation program. The treatment also decreased stemness and leukemia pathways at the transcriptome level and led to loss of binding of the fusion protein at critical regulators of these pathways. In contrast, our pharmacologic and genetic results indicate that the catalytic activity of KAT6A plays a more limited role in KMT2Ar leukemogenicity, while targeting the whole KAT6A protein dramatically affects leukemic potential in murine KMT2A::MLLT3 AML.
CONCLUSION
CONCLUSIONS
Our study indicates that inhibiting KAT6A KAT activity holds compelling promise for KAT6Ar AML patients. In contrast, targeted degradation of KAT6A, and not just its catalytic activity, may represent a more appropriate therapeutic approach for KMT2Ar AMLs.
Identifiants
pubmed: 39380002
doi: 10.1186/s13045-024-01610-0
pii: 10.1186/s13045-024-01610-0
doi:
Substances chimiques
Myeloid-Lymphoid Leukemia Protein
149025-06-9
KMT2A protein, human
0
Histone-Lysine N-Methyltransferase
EC 2.1.1.43
KAT6A protein, human
EC 2.3.1.48
Histone Acetyltransferases
EC 2.3.1.48
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
91Subventions
Organisme : Cancer Research UK Manchester Centre
ID : C19941/A31313
Organisme : Cancer Research UK
ID : C5759/A20971
Pays : United Kingdom
Organisme : Blood Cancer UK
ID : 19014
Pays : United Kingdom
Organisme : HORIZON EUROPE Marie Sklodowska-Curie Actions
ID : 658625
Organisme : Fonds National de la Recherche Luxembourg
ID : C20/BM/14582635
Organisme : Medical Research Council
ID : MR/P000673/1
Pays : United Kingdom
Organisme : Biotechnology and Biological Sciences Research Council
ID : BB/R007209/1
Pays : United Kingdom
Informations de copyright
© 2024. The Author(s).
Références
Shlush LI, Zandi S, Mitchell A, Chen WC, Brandwein JM, Gupta V, et al. Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia. Nature. 2014;506:328–33.
pubmed: 24522528
pmcid: 4991939
doi: 10.1038/nature13038
Abelson S, Collord G, Ng SWK, Weissbrod O, Mendelson Cohen N, Niemeyer E, et al. Prediction of acute myeloid leukaemia risk in healthy individuals. Nature. 2018;559:400–4.
pubmed: 29988082
pmcid: 6485381
doi: 10.1038/s41586-018-0317-6
Chopra M, Bohlander SK. The cell of origin and the leukemia stem cell in acute myeloid leukemia. Genes Chromosomes Cancer. 2019;58:850–8.
pubmed: 31471945
doi: 10.1002/gcc.22805
Kantarjian H, Kadia T, DiNardo C, Daver N, Borthakur G, Jabbour E, et al. Acute myeloid leukemia: current progress and future directions. Blood Cancer J. 2021;11:41.
pubmed: 33619261
pmcid: 7900255
doi: 10.1038/s41408-021-00425-3
Yang XJ, Ullah M. MOZ and MORF, two large MYSTic HATs in normal and cancer stem cells. Oncogene. 2007;26:5408–19.
pubmed: 17694082
doi: 10.1038/sj.onc.1210609
Perez-Campo FM, Costa G, Lie-a-Ling M, Kouskoff V, Lacaud G. The MYSTerious MOZ, a histone acetyltransferase with a key role in haematopoiesis. Immunology. 2013;139:161–5.
pubmed: 23347099
pmcid: 3647182
doi: 10.1111/imm.12072
Thomas T, Corcoran LM, Gugasyan R, Dixon MP, Brodnicki T, Nutt SL, et al. Monocytic leukemia zinc finger protein is essential for the development of long-term reconstituting hematopoietic stem cells. Genes Dev. 2006;20:1175–86.
pubmed: 16651658
pmcid: 1472476
doi: 10.1101/gad.1382606
Sheikh BN, Yang Y, Schreuder J, Nilsson SK, Bilardi R, Carotta S, et al. MOZ (KAT6A) is essential for the maintenance of classically defined adult hematopoietic stem cells. Blood. 2016;128:2307–18.
pubmed: 27663673
doi: 10.1182/blood-2015-10-676072
Katsumoto T, Aikawa Y, Iwama A, Ueda S, Ichikawa H, Ochiya T, et al. MOZ is essential for maintenance of hematopoietic stem cells. Genes Dev. 2006;20:1321–30.
pubmed: 16702405
pmcid: 1472906
doi: 10.1101/gad.1393106
Perez-Campo FM, Borrow J, Kouskoff V, Lacaud G. The histone acetyl transferase activity of monocytic leukemia zinc finger is critical for the proliferation of hematopoietic precursors. Blood. 2009;113:4866–74.
pubmed: 19264921
pmcid: 2686138
doi: 10.1182/blood-2008-04-152017
Perez-Campo FM, Costa G, Lie-a-Ling M, Stifani S, Kouskoff V, Lacaud G. MOZ-Mediated repression of p16INK4a is critical for the Self-Renewal of neural and hematopoietic stem cells. Stem Cells. 2014;32:1591–601.
pubmed: 24307508
doi: 10.1002/stem.1606
Kitabayashi I, Aikawa Y, Nguyen LA, Yokoyama A, Ohki M. Activation of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein. EMBO J. 2001;20:7184–96.
pubmed: 11742995
pmcid: 125775
doi: 10.1093/emboj/20.24.7184
Yang XJ. MOZ and MORF acetyltransferases: molecular interaction, animal development and human disease. Biochim Biophys Acta Mol Cell Res. 2015;1853:1818–26.
doi: 10.1016/j.bbamcr.2015.04.014
Paggetti J, Largeot A, Aucagne R, Jacquel A, Lagrange B, Yang XJ, et al. Crosstalk between leukemia-associated proteins MOZ and MLL regulates HOX gene expression in human cord blood CD34 cells. Oncogene. 2010;29:5019–31.
pubmed: 20581860
doi: 10.1038/onc.2010.254
Jung N, Dai B, Gentles AJ, Majeti R, Feinberg AP. An LSC epigenetic signature is largely mutation independent and implicates the HOXA cluster in AML pathogenesis. Nat Commun. 2015;6.
Au YZ, Gu M, De Braekeleer E, Gozdecka M, Aspris D, Tarumoto Y, et al. KAT7 is a genetic vulnerability of acute myeloid leukemias driven by MLL rearrangements. Leukemia. 2020. https://doi.org/10.1038/s41375-020-1001-z .
doi: 10.1038/s41375-020-1001-z
pubmed: 33067575
pmcid: 8179851
Yan F, Li J, Milosevic J, Petroni R, Liu S, Shi Z, et al. KAT6A and ENL Form an Epigenetic Transcriptional Control Module to drive critical leukemogenic gene-expression programs. Cancer Discov. 2022;12:792–811.
pubmed: 34853079
pmcid: 8916037
doi: 10.1158/2159-8290.CD-20-1459
Katsumoto T, Ogawara Y, Yamagata K, Aikawa Y, Goitsuka R, Nakamura T, et al. MOZ is critical for the development of MOZ/MLL fusion–induced leukemia through regulation of Hoxa9/Meis1 expression. Blood Adv. 2022;6:5527–37.
pubmed: 35947126
pmcid: 9577624
doi: 10.1182/bloodadvances.2020003490
DepMap B. DepMap 20Q2 Public. figshare. Dataset. 2020;: https://doi.org/10.6084/m9.figshare.12280541.v4
Meyers RM, Bryan JG, McFarland JM, Weir BA, Sizemore AE, Xu H, et al. Computational correction of copy number effect improves specificity of CRISPR-Cas9 essentiality screens in cancer cells. Nat Genet. 2017;49:1779–84.
pubmed: 29083409
pmcid: 5709193
doi: 10.1038/ng.3984
Dempster J, Rossen J, Kazachkova M, Pan J, Kugener G, Root D et al. Extracting Biological insights from the Project Achilles Genome-Scale CRISPR screens in Cancer Cell lines. BioRXiv. 2019. https://doi.org/10.1101/720243
Baell JB, Leaver DJ, Hermans SJ, Kelly GL, Brennan MS, Downer NL, et al. Inhibitors of histone acetyltransferases KAT6A/B induce senescence and arrest tumour growth. Nature. 2018;560:253–7.
pubmed: 30069049
doi: 10.1038/s41586-018-0387-5
Kayser S, Hills RK, Langova R, Kramer M, Guijarro F, Sustkova Z, et al. Characteristics and outcome of patients with acute myeloid leukaemia and t(8;16)(p11;p13): results from an International Collaborative Study*. Br J Haematol. 2021;192:832–42.
pubmed: 33529373
doi: 10.1111/bjh.17336
Rozman M, Camós M, Colomer D, Villamor N, Esteve J, Costa D, et al. Type I MOZ/CBP (MYST3/CREBBP) is the most common chimeric transcript in Acute myeloid leukemia with t(8;16)(p11;p13) translocation. Genes Chromosomes Cancer. 2004;40:140–5.
pubmed: 15101047
doi: 10.1002/gcc.20022
Wong KF, Yuen HL, Siu LLP, Pang A, Kwong YL. T(8;16)(P11;P13) predisposes to a transient but potentially recurring neonatal leukemia. Hum Pathol. 2008;39:1702–7.
pubmed: 18657848
doi: 10.1016/j.humpath.2008.02.018
Brown T, Swansbury J, Taj MM. Prognosis of patients with t(8;16)(p11;p13) acute myeloid leukemia. Leuk Lymphoma. 2012;53:338–41.
pubmed: 21846182
doi: 10.3109/10428194.2011.614703
Schmidt HH, Strehl S, Thaler D, Strunk D, Sill H, Linkesh W, et al. RT-PCR and FISH analysis of acute myeloid leukemia with t(8;16)(p11;p13) and chimeric MOZ and CBP transcripts: breakpoint cluster region and clinical implications. Leukemia. 2004;18:1115–21.
pubmed: 15085163
doi: 10.1038/sj.leu.2403353
Crowley JA, Wang Y, Rapoport AP, Ning Y. Detection of MOZ-CBP fusion in acute myeloid leukemia with 8;16 translocation [8]. Leukemia. 2005;19:2344–5.
pubmed: 16193081
doi: 10.1038/sj.leu.2403971
Kitabayashi I, Aikawa Y, Yokoyama A, Hosoda F, Nagai M, Kakazu N, et al. Fusion of MOZ and p300 histone acetyltransferases in acute monocytic leukemia with a t(8;22)(p11;q13) chromosome translocation. Leukemia. 2001;15:89–94.
pubmed: 11243405
doi: 10.1038/sj.leu.2401983
Chaffanet M, Gressin L, Preudhomme C, Soenen-Cornu V, Birnbaum D, Pébusque MJ. MOZ is fused to p300 in an acute monocytic leukemia with t(8;22). Genes Chromosomes Cancer. 2000;28:138–44.
pubmed: 10824998
doi: 10.1002/(SICI)1098-2264(200006)28:2<138::AID-GCC2>3.0.CO;2-2
Carapeti M, Aguiar RCT, Goldman JM, Cross NCP. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood. 1998;91:3127–33.
pubmed: 9558366
doi: 10.1182/blood.V91.9.3127
Carapeti M, Aguiar RCT, Watmore AE, Goldman JM, Cross NCP. Consistent fusion of MOZ and TIF2 in AML with inv(8)(p11q13). Cancer Genet Cytogenet. 1999;113:70–2.
pubmed: 10459350
doi: 10.1016/S0165-4608(99)00007-2
Liang J, Prouty L, Williams BJ, Dayton MA, Blanchard KL. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2. Blood. 1998;92:2118–22.
pubmed: 9731070
doi: 10.1182/blood.V92.6.2118
Klein BJ, Lalonde M-E, Côté J, Yang X-J, Kutateladze TG. Crosstalk between epigenetic readers regulates the MOZ/MORF HAT complexes. Epigenetics. 2014;9:186–93.
pubmed: 24169304
doi: 10.4161/epi.26792
Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273–84.
pubmed: 28701730
doi: 10.1038/leu.2017.213
Hodgkins A, Farne A, Perera S, Grego T, Parry-Smith DJ, Skarnes WC, et al. WGE: a CRISPR database for genome engineering. Bioinformatics. 2015;31:3078–80.
pubmed: 25979474
pmcid: 4565030
doi: 10.1093/bioinformatics/btv308
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445:661–5.
pubmed: 17251932
doi: 10.1038/nature05541
Muzumdar MD, Tasic B, Miyamichi K, Li L, Luo L. A global double-fluorescent Cre reporter mouse. Genesis. 2007;45:593–605.
pubmed: 17868096
doi: 10.1002/dvg.20335
Pelossof R, Fairchild L, Huang C-H, Widmer C, Sreedharan VT, Sinha N, et al. Prediction of potent shRNAs with a sequential classification algorithm. Nat Biotechnol. 2017;35:350–3.
pubmed: 28263295
pmcid: 5416823
doi: 10.1038/nbt.3807
Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21.
pubmed: 23104886
doi: 10.1093/bioinformatics/bts635
Liao Y, Smyth GK, Shi W. The R package rsubread is easier, faster, cheaper and better for alignment and quantification of RNA sequencing reads. Nucleic Acids Res. 2019;47:e47–47.
pubmed: 30783653
pmcid: 6486549
doi: 10.1093/nar/gkz114
Love MI, Huber W, Anders S. Moderated estimation of Fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
pubmed: 25516281
pmcid: 4302049
doi: 10.1186/s13059-014-0550-8
Stuart T, Butler A, Hoffman P, Hafemeister C, Papalexi E, Mauck WM, et al. Comprehensive Integration of Single-Cell Data. Cell. 2019;177:1888–e190221.
pubmed: 31178118
pmcid: 6687398
doi: 10.1016/j.cell.2019.05.031
Langmead B, Salzberg SL. Fast gapped-read alignment with Bowtie 2. Nat Methods. 2012;9:357–9.
pubmed: 22388286
pmcid: 3322381
doi: 10.1038/nmeth.1923
https://github.com/broadinstitute/picard.:https://github.com/broadinstitute/picard
Amemiya HM, Kundaje A, Boyle AP. The ENCODE Blacklist: identification of problematic regions of the genome. Sci Rep. 2019;9:9354.
pubmed: 31249361
pmcid: 6597582
doi: 10.1038/s41598-019-45839-z
Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Bernstein BE, et al. Model-based analysis of ChIP-Seq (MACS). Genome Biol. 2008;9:R137.
pubmed: 18798982
pmcid: 2592715
doi: 10.1186/gb-2008-9-9-r137
Lawrence M, Huber W, Pagès H, Aboyoun P, Carlson M, Gentleman R, et al. Software for Computing and Annotating genomic ranges. PLoS Comput Biol. 2013;9:e1003118.
pubmed: 23950696
pmcid: 3738458
doi: 10.1371/journal.pcbi.1003118
Ross-Innes CS, Stark R, Teschendorff AE, Holmes KA, Ali HR, Dunning MJ, et al. Differential oestrogen receptor binding is associated with clinical outcome in breast cancer. Nature. 2012;481:389–93.
pubmed: 22217937
pmcid: 3272464
doi: 10.1038/nature10730
Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545–50.
pubmed: 16199517
pmcid: 1239896
doi: 10.1073/pnas.0506580102
Weber LM, Jia Y, Stielow B, Gisselbrecht SS, Cao Y, Ren Y, et al. The histone acetyltransferase KAT6A is recruited to unmethylated CpG islands via a DNA binding winged helix domain. Nucleic Acids Res. 2023;51:574–94.
pubmed: 36537216
doi: 10.1093/nar/gkac1188
Becht DC, Klein BJ, Kanai A, Jang SM, Cox KL, Zhou B-R, et al. MORF and MOZ acetyltransferases target unmethylated CpG islands through the winged helix domain. Nat Commun. 2023;14:697.
pubmed: 36754959
pmcid: 9908889
doi: 10.1038/s41467-023-36368-5
Fan H, Lu J, Guo Y, Li D, Zhang ZM, Tsai YH, et al. BAHCC1 binds H3K27me3 via a conserved BAH module to mediate gene silencing and oncogenesis. Nat Genet. 2020;52:1384–96.
pubmed: 33139953
pmcid: 8330957
doi: 10.1038/s41588-020-00729-3
Collins CT, Hess JL. Deregulation of the HOXA9/MEIS1 axis in acute leukemia. Curr Opin Hematol. 2016;23:354–61.
pubmed: 27258906
pmcid: 5653247
doi: 10.1097/MOH.0000000000000245
Stavropoulou V, Kaspar S, Brault L, Sanders MA, Juge S, Morettini S, et al. MLL-AF9 expression in hematopoietic stem cells drives a highly invasive AML expressing EMT-Related genes linked to poor outcome. Cancer Cell. 2016;30:43–58.
pubmed: 27344946
doi: 10.1016/j.ccell.2016.05.011
Vervoort SJ, van Boxtel R, Coffer PJ. The role of SRY-related HMG box transcription factor 4 (SOX4) in tumorigenesis and metastasis: friend or foe? Oncogene. 2013;32:3397–409.
pubmed: 23246969
doi: 10.1038/onc.2012.506
Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128.
pubmed: 23586463
pmcid: 3637064
doi: 10.1186/1471-2105-14-128
Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90–7.
pubmed: 27141961
pmcid: 4987924
doi: 10.1093/nar/gkw377
Xie Z, Bailey A, Kuleshov MV, Clarke DJB, Evangelista JE, Jenkins SL, et al. Gene Set Knowledge Discovery with Enrichr. Curr Protoc. 2021;1:e90.
pubmed: 33780170
pmcid: 8152575
doi: 10.1002/cpz1.90
Haferlach T, Kohlmann A, Klein HU, Ruckert C, Dugas M, Williams PM, et al. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23:934–43.
pubmed: 19194466
doi: 10.1038/leu.2008.388
Camós M, Esteve J, Jares P, Colomer D, Rozman M, Villamor N, et al. Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res. 2006;66:6947–54.
pubmed: 16849538
doi: 10.1158/0008-5472.CAN-05-4601
Shima H, Yamagata K, Aikawa Y, Shino M, Koseki H, Shimada H, et al. Bromodomain-PHD finger protein 1 is critical for leukemogenesis associated with MOZ-TIF2 fusion. Int J Hematol. 2014;99:21–31.
pubmed: 24258712
doi: 10.1007/s12185-013-1466-x
MacPherson L, Anokye J, Yeung MM, Lam EYN, Chan YC, Weng CF, et al. HBO1 is required for the maintenance of leukaemia stem cells. Nature. 2020;577:266–70.
pubmed: 31827282
doi: 10.1038/s41586-019-1835-6
Fiskus W, Mill CP, Birdwell C, Davis JA, Das K, Boettcher S, et al. Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1. Blood Cancer J. 2023;13:1–13.
doi: 10.1038/s41408-023-00826-6
Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116:354–65.
pubmed: 20385793
doi: 10.1182/blood-2009-11-254441
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.
pubmed: 35797463
doi: 10.1182/blood.2022016867
Kennedy J, Goudie D, Blair E, Chandler K, Joss S, McKay V, et al. KAT6A syndrome: genotype–phenotype correlation in 76 patients with pathogenic KAT6A variants. Genet Sci. 2019;21:850–60.
Békés M, Langley DR, Crews CM. PROTAC targeted protein degraders: the past is prologue. Nat Rev Drug Discov. 2022;21:181–200.
pubmed: 35042991
pmcid: 8765495
doi: 10.1038/s41573-021-00371-6